All Search Results
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors
-
RESTORE: Re-do TAVR for TAVR Failure
RESTORE Study (REdo tranScatheter aortic valve replacement for Transcatheter aOrtic valve failuRE)
-
NMTT- Neuroblastoma Maintenance Therapy Trial Using DFMO
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
-
VALIDATION OF THE SURGIMEASURE TOOL FOR REAL-TIME INTRAOPERATIVE DISTANCE MEASUREMENT USING DE-IDENTIFIED ROBOTIC AND LAPAROSCOPIC VIDEO DATA
VALIDATION OF THE SURGIMEASURE TOOL FOR REAL-TIME INTRAOPERATIVE DISTANCE MEASUREMENT USING DE-IDENTIFIED ROBOTIC AND LAPAROSCOPIC VIDEO DATA
-
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of IBS-C in Pediatric Patients 12 to 18 Years Old
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable
-
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
-
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
-
Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
-
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
S25.184.07
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
